REMEGEN (09995): Huang Guobin appointed as independent non-executive director.
Rongchang Biology (09995) announced that Mr. Huang Guobin was appointed as an independent director of the second board of directors at the extraordinary general meeting.
REMEGEN (09995) announced that Mr. Huang Guobin has been appointed as an independent non-executive director of the second board of directors at the temporary shareholders' meeting. Mr. Huang's appointment is effective immediately after the temporary shareholders' meeting and will continue until the end of the second term of the board of directors. Mr. Huang has also been appointed as the chairman of the nomination committee and a member of the strategic committee, effective from his appointment as an independent non-executive director at the temporary shareholders' meeting until the end of the second term of the board of directors.
After the temporary shareholders' meeting, Dr. Ma Lan will no longer serve as an independent non-executive director, chairman of the nomination committee, and member of the strategic committee.
Related Articles

Netflix (NFLX.US) has promised to maintain movie theater releases while exploring the acquisition of Warner Bros. Discovery Company's (WBD.US) streaming business.

HK Stock Market Move | HENLIUS (02696) is now up more than 4%, POHERDY has been approved for listing in the United States, covering all indications of original research products.

HK Stock Market Move | MAOYAN ENT (01896) falls more than 2%, reports claim that the ticket refund rate for the movie "Demon Slayer" has greatly increased.
Netflix (NFLX.US) has promised to maintain movie theater releases while exploring the acquisition of Warner Bros. Discovery Company's (WBD.US) streaming business.

HK Stock Market Move | HENLIUS (02696) is now up more than 4%, POHERDY has been approved for listing in the United States, covering all indications of original research products.

HK Stock Market Move | MAOYAN ENT (01896) falls more than 2%, reports claim that the ticket refund rate for the movie "Demon Slayer" has greatly increased.

RECOMMEND

Tech Stocks, Crypto, and Gold Slump; U.S. Equities Break Key Support Amid Broad-based Sell-off
18/11/2025

Goldman Sachs’ Ten-year Investment Outlook: Artificial Intelligence and Emerging Markets As Core Growth Engines
18/11/2025

Consensus On Multiple Outcomes, Easing Trade Tensions, China–Germany High-level Financial Dialogue Convened In Beijing
18/11/2025


